Wall Street price-target analytics for Lyell Immunopharma (LYEL) imply potential upside of 176% based on the average of analysts’ targets, though the article notes this metric’s reliability is questionable. The piece points to a positive trend in earnings estimate revisions that could support additional stock upside if the revisions persist.
Wall Street price-target analytics for Lyell Immunopharma (LYEL) imply potential upside of 176% based on the average of analysts’ targets, though the article notes this metric’s reliability is questionable. The piece points to a positive trend in earnings estimate revisions that could support additional stock upside if the revisions persist.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
